Julie Rubinstein, President and Chief Operating Officer of Adaptive Biotechnologies Corporation, has reported a series of stock transactions involving the company's common stock. The filings, made on October 8, 2026, are part of a structured trading plan that reflects her ongoing management of equity in the company.
Adaptive Biotechnologies Corporation, based in Seattle, Washington, operates in the life sciences sector, specifically focusing on biological products. The company is known for its innovative approaches in the field of immunology and personalized medicine. The recent SEC filings indicate that Rubinstein executed both acquisitions and disposals of shares, showcasing her active role in the company.
The filing details several transactions that took place on October 6, 2026, and October 8, 2026. Rubinstein acquired 11,881 shares at a price of $12.14 per share, while also disposing of shares at various prices ranging from $25.23 to $30.68. Following these transactions, she holds a total of 377,802 shares in Adaptive Biotechnologies.
"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025," the filing states.
This activity may affect shareholders and potential investors as it reflects Rubinstein's confidence in the company's future. The structured nature of these transactions, executed under a trading plan, suggests a strategic approach to managing her stake without the appearance of insider trading.
Looking ahead, it remains to be seen how these transactions will impact Adaptive Biotechnologies' stock performance and investor sentiment. The filing does not specify any upcoming events or additional filings related to these transactions.